Merck & Co. clears a short-term technical mark, shares extend their recent advance

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-24, 08:25.

Merck & Co., Inc. (US58933Y1055) has pushed above its 20-day moving average in recent NYSE sessions, coinciding with a 3.6 percent gain to a 119.71 dollar close on June 23, 2026, according to MarketBeat and Zacks. The large-cap S&P 500 healthcare stock is also benefiting from positive pipeline updates, led by late-stage data for its ulcerative colitis drug tulisokibart.

Technical picture after the 20-day break

Zacks notes that Merck recently overtook its 20-day moving average, framing the move as a short-term bullish signal for the shares. The commentary highlights the breakout above this short-term support level as an indication that near-term momentum has improved, rather than a guarantee of sustained upside.

Separate price data from Stockscan and MarketBeat show Merck shares around 119.60 to 119.71 dollars, up roughly 3.6 percent or about 4.1 dollars on June 23, with after-hours trading marginally lower at 119.55 dollars. This advance leaves the stock trading meaningfully above the short-term average, underlining the break described in the Zacks technical note.

Pipeline updates support the trend

MarketBeat attributes the recent strength in Merck shares to a series of upbeat pipeline and product updates, singling out positive late-stage data for its ulcerative colitis candidate tulisokibart as a key driver. The site summarizes that investors are responding to trial results that could add a new revenue stream in immunology if the drug progresses successfully through regulatory review.

Beyond tulisokibart, Merck’s pipeline spans oncology, vaccines and infectious diseases, which MarketBeat and other outlets present as a diversified innovation base in the U.S. large-cap pharmaceutical peer group, alongside names such as Pfizer and Bristol Myers Squibb. The current move in Merck shares comes against a broader backdrop where healthcare components of the S&P 500 are seeing renewed interest after periods of more muted performance.

The products and franchises behind the stock

Merck’s revenue base is anchored by oncology and vaccines, with blockbuster cancer therapy Keytruda and human papillomavirus vaccine Gardasil among its largest products, according to company filings and market data. Keytruda is approved across multiple tumor types and has become a key driver of Merck’s cash flow and R&D reinvestment.

Where the Merck & Co. shares trade

The Merck & Co., Inc. shares (US58933Y1055) trade on the NYSE under the ticker MRK and last closed at 119.71 dollars on 2026-06-23 at 15:58 Eastern Time, with after-hours indications around 119.55 dollars.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources cited and may change over time.